共 18 条
[11]
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology[J] . R Pahwa,S A. Factor,K E. Lyons,W G. Ondo,G Gronseth,H Bronte-Stewart,M Hallett,J Miyasaki,J Stevens,W J. Weiner.Neurology . 2006 (7)
[12]
Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai[J] . Zhen-Xin Zhang,Gustavo C Roman,Zhen Hong,Cheng-Bing Wu,Qiu-Ming Qu,Jue-Bing Huang,Bing Zhou,Zhi-Ping Geng,Ji-Xing Wu,Hong-Bo Wen,Heng Zhao,Gwendolyn EP Zahner.The Lancet . 2005 (9459)
[13]
Other pharmacological treatments for motor complications and dyskinesias[J] . CherylWaters.Mov. Disord. . 2005 (S11)
[14]
Switching and combining of dopamine agonists
[J].
Journal of Neurology,
2004, 251
:vi19-vi23
Susann Junghanns
;
Theresa Glöckler
;
Heinz Reichmann
.
[15]
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study[J] . Alan L.Whone,Ray L.Watts,A. JonStoessl,MargaretDavis,SvenReske,ClaudeNahmias,Anthony E.Lang,OlivierRascol,Maria J.Ribeiro,PhilippeRemy,Werner H.Poewe,Robert A.Hauser,David J.Brooks.Ann Neurol. . 2003 (1)
[16]
Initial agonist treatment of Parkinson disease: A critique[J] . Roger L. Albin,Kirk A. Frey.Neurology . 2003 (3)
[17]
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease .2 M. Horstink,E. Tolosa,U. Bonuccelli,G. Deuschl,A. Friedman,P. Kanovsky,J. P. Larsen,A. Lees,W. Oertel,W. Poewe,O. Rascol,C. Sampaio. European Journal of Neurology . 2006
[18]
Continuous dopamine-receptor stimulation in early Parkinson's disease[J] . C. Warren Olanow,Anthony H.V. Schapira,Olivier Rascol.Trends in Neurosciences . 2000